stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Free cash flow margin
Tango Therapeutics, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 0.00%, up 224.3 percentage points from fiscal 2025 (−224.3%). Over the past ten years it has ranged from −469.7% (fiscal 2022) to 900.8% (fiscal 2020); the current reading is higher than 67% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −224.3% | 90.07 |
| FY2024 | −314.4% | 12.80 |
| FY2023 | −327.2% | 142.54 |
| FY2022 | −469.7% | (304.06) |
| FY2021 | −165.7% | (1,066.50) |
| FY2020 | 900.8% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 6.82% |
| XENE Xenon Pharmaceuticals Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | −57.0% |
| ABCL AbCellera Biologics Inc. compare | −180.8% |
| RLAY Relay Therapeutics, Inc. compare | −1,924.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement